



May 11, 2015

Esperion Therapeutics to Present at the UBS Global Healthcare Conference

Presentation and Webcast on Monday, May 18, 2015 at 9:30 A.M. Eastern Time

ANN ARBOR, MI -- (Marketwired) -- 05/11/15 -- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced president and chief executive officer, Tim M. Mayleben, will present at the UBS Global Healthcare Conference in New York City on Monday, May 18, 2015 at 9:30 A.M. Eastern Time.

A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the presentation will be available approximately one hour after completion and will be archived on the Company's website for 90 days following the event.

Esperion's Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two preclinical product candidates.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a first-in-class, orally available, once-daily small molecule designed to lower elevated LDL-cholesterol levels and avoid the side effects associated with currently available LDL-cholesterol lowering therapies. ETC-1002 is being developed for patients with primary hyperlipidemia and mixed dyslipidemia. For more information, please visit www.esperion.com and follow us on Twitter at <https://twitter.com/EsperionInc>.

Media Contact:

Elliot Fox
W2O Group
212.257.6724
efox@w2ogroup.com

Investor Contact:

Barbara Ryan
Clermont Partners
203.274.2825
bryan@esperion.com

Source: Esperion Therapeutics, Inc.

News Provided by Acquire Media